Gliclazide

ALIMENTARY TRACT AND METABOLISM

Key facts

Gliclazide is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1972. DrugCentral lists 3 molecular targets, including ABCC8|KCNJ11, ABCC9|KCNJ11 and AKR1C3. Recorded indications include Diabetes mellitus type 2.

• Molecular targets: ABCC8|KCNJ11, ABCC9|KCNJ11 and AKR1C3 (3 listed in DrugCentral).
• Indications: Diabetes mellitus type 2.
• ATC code: A10BB09 (Sulfonylureas).
• Molecular formula: C15H21N3O3S; molecular weight 323.41 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Diabetes mellitus type 2

Mechanism & targets

Molecular targets (3)

Target	Gene	Action	Activity
Sulfonylurea receptor 1, Kir6.2	ABCC8|KCNJ11	blocker	Kd 6.22
Sulfonylurea receptor 2, Kir6.2	ABCC9|KCNJ11	blocker	Ki 5.13
Aldo-keto reductase family 1 member C3	AKR1C3	unknown	IC50 4.71

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1972-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
A10BB09	ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Sulfonylureas

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• Swissmedic label: G6PD · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hypoglycaemia	1598.5
Lactic acidosis	1398.1
Acute kidney injury	1093.0
Diabetes mellitus inadequate control	897.1
Diabetic ketoacidosis	714.6
Hyperkalaemia	622.8
Hyperglycaemia	408.2
Euglycaemic diabetic ketoacidosis	381.0
Gangrene	362.3
Arterial occlusive disease	346.7
Neurologic neglect syndrome	327.4
Carotid artery thrombosis	327.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Gliclazide is on its molecule page.

• Molecular formula: C₁₅H₂₁N₃O₃S
• Molecular weight: 323.41 g/mol
• CAS number: 21187-98-4
• InChIKey: BOVGTQGAOIONJV-UHFFFAOYSA-N
• PubChem CID: 3475

CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CC2CCCC2C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Gliclazide used for?

DrugCentral lists the following indications for Gliclazide: Diabetes mellitus type 2.

How does Gliclazide work?

Its molecular targets in DrugCentral include ABCC8|KCNJ11 (blocker), ABCC9|KCNJ11 (blocker) and AKR1C3.

When was Gliclazide first approved?

Gliclazide was first approved by the YEAR INTRODUCED in 1972.

What is the chemical formula of Gliclazide?

Gliclazide has the molecular formula C15H21N3O3S and a molecular weight of 323.41 g/mol.

Sources

• DrugCentral drug card 1299 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL427216 — compound record and bioactivity
• PubChem CID 3475 — chemical identifiers
• DrugBank DB01120 — drug record
• FDA UNII G4PX8C4HKV — substance identity
• UniProt P42330 (AKR1C3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.